Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6128863 | Clinical Microbiology and Infection | 2016 | 16 Pages |
Abstract
Hepatitis B core-related antigen (HBcrAg), a new serum marker, may be useful in monitoring chronic hepatitis B infection. HBcrAg was measured in 175 hepatitis B e antigen-positive patients treated with entecavir (ETV) with or without peginterferon (PEG-IFN) add-on therapy. Decline in HBcrAg was stronger in patients with vs. without combined response (ETV: â3.22 vs. â1.71 log U/mL, p <0.001; PEG-IFN add-on: â3.16 vs. â1.83 IU/mL, p <0.001) and in patients with vs. without hepatitis B surface antigen (HBsAg) response (ETV: â2.60 vs. â1.74 log U/mL, p <0.001; PEG-IFN add-on: â2.38 vs. â2.15 log U/mL, p = 0.31). HBcrAg was associated with combined response (adjusted odds ratio 0.3, 95% confidence interval 0.2-0.5, p <0.001), but was not superior to quantitative HBsAg (qHBsAg).
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
Authors
M.J.H. van Campenhout, W.P. Brouwer, G.W. van Oord, Q. Xie, Q. Zhang, N. Zhang, S. Guo, F. Tabak, A. Streinu-Cercel, J. Wang, S.D. Pas, M.J. Sonneveld, R.J. de Knegt, A. Boonstra, B.E. Hansen, H.L.A. Janssen,